Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative FOLFIRINOX in Resectable Pancreatic Adenocarcinoma
NCT02782182Phase 1Terminated
- Sponsor
- University of Chicago
- Start
- Jun 2016
- Primary completion
- Mar 2018
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxaliplatin, folinic acid, irinotecan and fluorouracil in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Chicago. Primary endpoint: Percentage of patients able to complete 4 months of preoperative chemotherapy and undergo a resection. Started Jun 2016; status: terminated.
02
Drugs
oxaliplatinfolinic acidirinotecanfluorouracil
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02782182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02782182.